Archives
ACG: 2000 to 2022 Saw Rise in Early-Onset CRC Mortality in the United States
Increase in mortality seen in both early- and late-stage tumors
ACG: Hormone Therapy Tied to Higher Risk for New Irritable Bowel Syndrome
Hormone replacement therapy also tied to elevated gastrointestinal symptoms and diagnostic testing
ASN: Atrasentan Significantly and Clinically Meaningfully Cuts Proteinuria
Findings seen in patients with IgA nephropathy, compared with placebo
ASN: Hypertension Most Common Cardiovascular Comorbidity Seen With Dialysis
The next most common conditions included atherosclerotic heart disease and congestive heart failure
ACAAI: ICS + Formoterol and ICS + SABA Better Than SABA Alone for Asthma
Inhaled corticosteroid with short-acting β agonists or long-acting β agonist formoterol linked to reduction in exacerbations, improved control
ACS: Many Cancer Patients Face Lasting Financial Difficulties
Patients with cancer have higher rates of total collections, medical collections, and bankruptcy
ACAAI: 2013 to 2023 Saw Rise in Pediatric Psych Referrals Tied to Food Allergies
During the study period, there was an 11-fold increase in food allergy-related referrals
ASN: Recurrent UTIs Impact eGFR in Children With Vesicoureteral Reflux
Recurrent urinary tract infections linked to decrease of up to 27 mL/min/1.73 m² in estimated glomerular filtration rate
ACG: Fewer Overt Hepatic Encephalopathy Episodes Seen With Rifaximin
Rifaximin monotherapy reduces risk for breakthrough OHE episode and results in a lower mortality rate than lactulose monotherapy
ASN: Empagliflozin Offers Lasting Cardiorenal Benefit in CKD Patients
Empagliflozin offers cardiorenal benefits for up to 12 months after discontinuation among CKD patients at risk for progression
